CLINICAL_TRIALS
trial_result
· 2018-01-05
Clinical Trial Update: A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease [Phase 2]
Summary
Phase 2 pilot study of alpha-1-antitrypsin for steroid-refractory acute graft-versus-host disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Michigan Rogel Cancer Center | Conditions: Graft vs Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-01-05